Norway· NO-ID_D8790A5B-27DC-47B8-9060-491F987B35F9
Ilaris
A canakinumab product containing canakinumab, registered in Norway by Novartis Europharm Limited (1). The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Canakinumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC08 (canakinumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Canakinumab · ATC L04AC08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Canakinumab
- Manufacturer
- Novartis Europharm Limited (1)
- Country
- Norway (NO)
- ATC code
- L04AC08
- ATC class
- Canakinumab
- Defined daily dose
- 2.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_D8790A5B-27DC-47B8-9060-491F987B35F9
- no_varenummer4442601NOK 145562.7
- gtin7612797360590
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
374 interactions on record for canakinumab.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Canakinumab · interactions on record
374 records
- 30 severe
- 337 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Canakinumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandIlaris
- BelgiumIlaris 150 mg/mlNovartis Europharm
- CzechiaILARISNovartis Europharm Limited, Dublin
- SpainILARIS 150 MG/ML SOLUCION INYECTABLENovartis Europharm Limited
- PolandIlarisNovartis Europharm Limited
- SwedenIlaris 150 mg/ml Injektionsvätska, lösningNovartis Europharm Limited
- United KingdomIlaris 150mg powder for solution for injection vialsNovartis Pharmaceuticals UK Ltd
- FinlandIlarisNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Ilaris
- Liechtenstein · Ilaris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dddd277e-acdb-4128-b37c-ea92c073efbe GET /v1/drugs/dddd277e-acdb-4128-b37c-ea92c073efbe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Kanakinumab",
"merkevare_id": "ID_D8790A5B-27DC-47B8-9060-491F987B35F9",
"name_form_strength": "Ilaris inj, oppl 150 mg/ml",
"prescription_group": "C"
}See everything about canakinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.